WO2025002962 - USE OF A MPS1 INHIBITOR FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA
National phase entry is expected:
Publication Number
WO/2025/002962
Publication Date
02.01.2025
International Application No.
PCT/EP2024/067203
International Filing Date
20.06.2024
Title **
[English]
USE OF A MPS1 INHIBITOR FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA
[French]
UTILISATION D'UN INHIBITEUR DE MPS1 POUR LE TRAITEMENT DU CARCINOME HÉPATOCELLULAIRE
Applicants **
NERVIANO MEDICAL SCIENCES S.R.L.
Viale Pasteur, 10
20014 Nerviano (MI), IT
Inventors
COLOMBO, Riccardo
Via Strera 3/A
28047 Oleggio, IT
GASPARRI, Fabio
Via Palestro, 17
20015 Parabiago (MI), IT
TEXIDO ROMERO, Gemma
Viale Pasteur 10
20014 Nerviano, IT
MARUZZELLI, Sara
Viale Pasteur 10
20014 Nerviano, IT
Priority Data
23182638.9
30.06.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 961 | |
| EPO | Filing, Examination | 4626 | |
| Japan | Filing | 596 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3910 |
Total: 10668 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention provides a low molecular weight ATP-competitive MPS1 inhibitor for use in the treatment of hepatocellular carcinoma (HCC).[French]
L'invention concerne un inhibiteur de MPS1 compétitif de l'ATP de faible poids moléculaire destiné à être utilisé dans le traitement du carcinome hépatocellulaire (HCC).